FDA Grants Breakthrough Status to Biopharma’s Lead Candidate for Liver Disease
Article from streetwisereports.com discussing how the advancements to Phase 2b are the most valuable asset to CymaBay and many Biotech companies. The research report also addresses how the analyst Yasmeen Rahimi reported that CymaBay Therapeutics had a strong Q1/19 with respect to continued execution of its clinical programs for its most advanced therapeutic, seladelpar, in nonalcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC).
Periportal steatosis of the liver. Source: Nephron